Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic...
61 insider purchases on record · latest filing 2026-08-13.
Insiders have also filed 21 sale transactions at ALT.